Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2010
Date: 2011-01-13
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, European Economic Area, market approval, marketing, medicinal product, withdrawal from the market








C_2011008EN.01000701.xml










13.1.2011   


EN


Official Journal of the European Union


C 8/7





Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2010
2011/C 8/07

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2010, at their meeting on 1 October 2010:






Annex I


List of new marketing authorisations




Annex II


List of renewed marketing authorisations




Annex III


List of extended marketing authorisations




Annex IV


List of withdrawn marketing authorisations




Annex V


List of suspended marketing authorisations






ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2010:








EU-Number


Product


Country


Date of authorisation




EU/1/06/367/001/NO-012/NO


Diacomit


Norway


5.2.2010




EU/1/08/476/005-006


Adcirca


Liechtenstein


28.2.2010




EU/1/09/571/001/IS


Pandemic Influenza Vaccine H5N1 Baxter


Iceland


27.1.2010




EU/1/09/577/001/NO-004/NO


Foclivia


Norway


18.2.2010




EU/1/09/583/001/NO-072/NO


Irbesartan/Hydrochlorothiazide Teva


Norway


18.1.2010




EU/1/09/583/001-072


Irbesartan/Hydrochlorothiazide Teva


Liechtenstein


28.2.2010




EU/1/09/584/001-018


Sildenafil Teva


Liechtenstein


28.2.2010




EU/1/09/585/001/NO-018/NO


Rivastigmine 1A


Norway


9.3.2010




EU/1/09/585/001-018/IS


Rivastigmine 1A


Iceland


2.3.2010




EU/1/09/586/001/NO-010/NO


Oslif Breezhaler


Norway


27.1.2010




EU/1/09/586/001-010


Oslif Breezhaler


Liechtenstein


28.2.2010




EU/1/09/587/001/NO-017/NO


Olanzapine Glenmark


Norway


3.2.2010




EU/1/09/587/001-017


Olanzapine Glenmark


Liechtenstein


28.2.2010




EU/1/09/587/001-017/IS


Olanzapine Glenmark


Iceland


25.1.2010




EU/1/09/588/001/NO-012/NO


Olanzapine Glenmark Europe


Norway


6.2.2010




EU/1/09/588/001-012


Olanzapine Glenmark Europe


Liechtenstein


28.2.2010




EU/1/09/588/001-012/IS


Olanzapine Glenmark Europe


Iceland


25.1.2010




EU/1/09/589/001/NO-018/NO


Rivastigmine Hexal


Norway


9.3.2010




EU/1/09/589/001-018


Rivastigmine Hexal


Liechtenstein


28.2.2010




EU/1/09/589/001-018/IS


Rivastigmine Hexal


Iceland


4.3.2010




EU/1/09/590/001/NO-006/NO


Prevenar 13


Norway


18.1.2010




EU/1/09/590/001-006


Prevenar 13


Liechtenstein


28.2.2010




EU/1/09/592/001/NO-005/NO


Olazax Disperzi


Norway


4.2.2010




EU/1/09/592/001-005


Olazax Disperzi


Liechtenstein


28.2.2010




EU/1/09/592/001-005/IS


Olazax Disperzi


Iceland


25.1.2010




EU/1/09/593/001/NO-010/NO


Onbrez Breezhaler


Norway


6.1.2010




EU/1/09/593/001-010


Onbrez Breezhaler


Liechtenstein


28.2.2010




EU/1/09/594/001/NO-010/NO


Hirobriz Breezhaler


Norway


28.1.2010




EU/1/09/594/001-010


Hirobriz Breezhaler


Liechtenstein


28.2.2010




EU/1/09/595/001/NO-015/NO


Sildenafil Actavis


Norway


13.1.2010




EU/1/09/595/001-015/IS


Sildenafil Actavis


Iceland


7.1.2010




EU/1/09/596/001/NO-014/NO


Lamuvidine Teva Pharma BV


Norway


11.1.2010




EU/1/09/596/001-014


Lamivudine Teva Pharma BV


Liechtenstein


28.2.2010




EU/1/09/596/001-014/IS


Lamivudine Teva Pharma BV


Iceland


1.3.2010




EU/1/09/597/001/NO-005/NO


Olazax


Norway


4.2.2010




EU/1/09/597/001-005/IS


Olazax


Iceland


25.1.2010




EU/1/09/598/001/NO-004/NO


Nevirapine Teva


Norway


11.1.2010




EU/1/09/598/001-004/IS


Nevirapine Teva


Iceland


1.3.2010




EU/1/09/599/001/NO-018/NO


Rivastigmine Sandoz


Norway


9.3.2010




EU/1/09/599/001-018/IS


Rivastigmine Sandoz


Iceland


4.3.2010




EU/1/09/600/001/IS


Zutectra


Iceland


24.2.2010




EU/1/09/600/001/NO


Zutectra


Norway


11.1.2010




EU/1/09/601/001


Zenas


Liechtenstein


28.2.2010




EU/1/09/601/001/NO


Zenas


Norway


4.2.2010




EU/1/09/601/001/IS


Zenas


Iceland


20.1.2010




EU/1/09/602/001/NO-002/NO


Scintimun


Norway


25.1.2010




EU/1/09/602/001-002


Scintimun


Liechtenstein


28.2.2010




EU/1/09/602/001-002/IS


Scintimun


Iceland


21.1.2010




EU/1/09/603/001/NO-012/NO


Sildenafil ratiopharm


Norway


13.1.2010




EU/1/09/603/001-012


Sildenafil ratiopharm


Liechtenstein


28.2.2010




EU/1/09/603/001-012/IS


Sildenafil ratiopharm


Iceland


18.1.2010




EU/1/09/604/001/NO-010/NO


Leflunomide Winthrop


Norway


4.2.2010




EU/1/09/604/001-010


Leflunomide Winthrop


Liechtenstein


28.2.2010




EU/1/09/604/001-010/IS


Leflunomide Winthrop


Iceland


22.1.2010




EU/1/09/605/001-012


Temomedac


Liechtenstein


28.2.2010




EU/1/09/605/001-012/IS


Temomedac


Iceland


24.2.2010




EU/1/09/606/001/NO-012/NO


Temozolomide


Norway


15.2.2010




EU/1/09/606/001-012


Temozolomide


Liechtenstein


28.2.2010




EU/1/09/606/001-012/IS


Temozolomide


Iceland


16.2.2010




EU/1/09/607/001/NO-014/NO


Silodyx


Norway


9.2.2010




EU/1/09/607/001-014


Silodyx


Liechtenstein


28.2.2010




EU/1/09/607/001-014/IS


Silodyx


Iceland


16.3.2010




EU/1/09/608/001/NO-014/NO


Urorec


Norway


9.2.2010




EU/1/09/608/001-014


Urorec


Liechtenstein


28.2.2010




EU/1/09/608/001-014/IS


Urorec


Iceland


16.3.2010




EU/1/09/609/001/NO-002/NO


Elonva


Norway


11.3.2010




EU/1/09/609/001-002


Elonva


Liechtenstein


28.2.2010




EU/1/09/609/001-002/IS


Elonva


Iceland


10.2.2010




EU/1/09/610/001/NO-030/NO


Telmisartan Teva


Norway


2.3.2010




EU/1/09/610/001-030


Telmisartan Teva


Liechtenstein


28.2.2010




EU/1/09/610/001-030/IS


Telmisartan Teva


Iceland


16.3.2010




EU/1/09/611/001/NO-002/NO


Docetaxel Teva


Norway


26.2.2010




EU/1/09/611/001-002


Docetaxel Teva


Liechtenstein


28.2.2010




EU/1/09/611/001-002/IS


Docetaxel Teva


Iceland


23.2.2010




EU/1/10/612/001/NO-006/NO


Revolade


Norway


25.3.2010




EU/1/10/612/001-006


Revolade


Liechtenstein


30.4.2010




EU/1/10/612/001-006/IS


Revolade


Iceland


7.4.2010




EU/1/10/613/001/NO-002/NO


ImmunoGam


Norway


19.4.2010




EU/1/10/613/001-002


ImmunoGam


Liechtenstein


30.4.2010




EU/1/10/613/001-002/IS


ImmunoGam


Iceland


28.4.2010




EU/1/10/614/001


Menveo


Liechtenstein


30.4.2010




EU/1/10/614/001/IS


Menveo


Iceland


15.6.2010




EU/1/10/614/001/NO


Menveo


Norway


21.4.2010




EU/1/10/615/001/NO-024/NO


Temozolomide Hospira


Norway


24.3.2010




EU/1/10/615/001-024


Temozolomide Hospira


Liechtenstein


30.4.2010




EU/1/10/615/001-024/IS


Temozolomide Hospira


Iceland


3.5.2010




EU/1/10/616/001/NO-024/NO


Temozolomide Hexal


Norway


26.4.2010




EU/1/10/616/001-024


Temozolomide Hexal


Liechtenstein


30.4.2010




EU/1/10/616/001-024/IS


Temozolomide Hexal


Iceland


27.4.2010




EU/1/10/617/001/NO-024/NO


Temozolomide Sandoz


Norway


26.4.2010




EU/1/10/617/001-024


Temozolomide Sandoz


Liechtenstein


30.4.2010




EU/1/10/617/001-024/IS


Temozolomide Sandoz


Iceland


27.4.2010




EU/1/10/618/001-004


Prolia


Liechtenstein


30.6.2010




EU/1/10/618/001-004/IS


Prolia


Iceland


23.6.2010




EU/1/10/619/001/NO-014/NO


DuoPlavin


Norway


23.3.2010




EU/1/10/619/001-014


DuoPlavin


Liechtenstein


30.4.2010




EU/1/10/619/001-014/IS


DuoPlavin


Iceland


21.4.2010




EU/1/10/620/001/NO-016/NO


Ristfor


Norway


3.6.2010




EU/1/10/620/001-016


Ristfor


Liechtenstein


30.4.2010




EU/1/10/620/001-016/IS


Ristfor


Iceland


5.5.2010




EU/1/10/621/001/NO-018/NO


Ristaben


Norway


3.6.2010




EU/1/10/621/001-018


Ristaben


Liechtenstein


30.4.2010




EU/1/10/621/001-018/IS


Ristaben


Iceland


5.5.2010




EU/1/10/622/001/NO-002/NO


Tepadina


Norway


25.3.2010




EU/1/10/622/001-002/IS


Tepadina


Iceland


21.4.2010




EU/1/10/622/001-002


Tepadina


Liechtenstein


30.4.2010




EU/1/10/623/001/NO-014/NO


DuoCover


Norway


23.3.2010




EU/1/10/623/001-014


DuoCover


Liechtenstein


30.4.2010




EU/1/10/623/001-014/IS


DuoCover


Iceland


21.4.2010




EU/1/10/624/001


Arepanrix


Liechtenstein


30.4.2010




EU/1/10/624/001/IS


Arepanrix


Iceland


21.5.2010




EU/1/10/625/001/NO-002/NO


Arzerra


Norway


12.5.2010




EU/1/10/625/001-002


Arzerra


Liechtenstein


30.4.2010




EU/1/10/625/001-002/IS


Arzerra


Iceland


17.5.2010




EU/1/10/626/001/NO-004/NO


Ribavirin BioPartners


Norway


22.4.2010




EU/1/10/626/001-004/IS


Ribavirin BioPartners


Iceland


17.5.2010




EU/1/10/627/001/NO-003/NO


Raloxifene Teva


Norway


31.5.2010




EU/1/10/627/001-003


Raloxifene Teva


Liechtenstein


30.4.2010




EU/1/10/627/001-003/IS


Raloxifene Teva


Iceland


18.6.2010




EU/1/10/628/001/NO-004/NO


Votrient


Norway


28.6.2010




EU/1/10/628/001-004


Votrient


Liechtenstein


30.6.2010




EU/1/10/628/001-004/IS


Votrient


Iceland


28.6.2010




EU/1/10/629/001


Humenza


Liechtenstein


30.6.2010




EU/1/10/629/001/IS


Humenza


Iceland


28.6.2010




EU/1/10/630/001/NO-002/NO


Docefrez


Norway


7.6.2010




EU/1/10/630/001-002


Docefrez


Liechtenstein


30.6.2010




EU/1/10/630/001-002/IS


Docefrez


Iceland


29.6.2010




EU/1/10/631/001-009


Nivestim


Liechtenstein


30.6.2010




EU/1/10/632/001-021


Tolura


Liechtenstein


30.6.2010




EU/1/10/633/001/NO-002/NO


Topotecan Hospira


Norway


22.6.2010




EU/1/10/633/001-002


Topotecan Hospira


Liechtenstein


30.6.2010




EU/1/10/634/001-004


Ribaverin Three Rivers


Liechtenstein


30.6.2010




EU/1/10/634/001-004/IS


Ribavirin Three Rivers


Iceland


28.6.2010




EU/1/10/635/001-014


Olanzapine Apotex


Liechtenstein


30.6.2010




EU/1/10/635/001-014/IS


Olanzapine Apotex


Iceland


28.6.2010




EU/2/08/085/001/NO


Easotic


Norway


4.5.2010




EU/2/08/090/001-008/IS


Loxicom


Iceland


23.2.2010




EU/2/09/096/001/NO-002/NO


Leucogen


Norway


8.2.2010




EU/2/09/101/001/NO-010/NO


Zolvix


Norway


8.2.2010




EU/2/09/101/001-010/IS


Zolvix


Iceland


4.3.2010




EU/2/09/102/001/NO-006/NO


Gripovac 3


Norway


21.4.2010




EU/2/09/102/001-006


Gripovac 3


Liechtenstein


28.2.2010




EU/2/09/102/001-006/IS


Gripovac 3


Iceland


4.3.2010




EU/2/09/103/001-006


Respiporc FLU3


Liechtenstein


28.2.2010




EU/2/09/103/001-006/IS


Respiporc FLU3


Iceland


4.3.2010




EU/2/09/104/001/NO-002/NO


Zulvac 8 Ovis


Norway


11.2.2010




EU/2/09/104/001-002


Zulvac 8 Ovis


Liechtenstein


28.2.2010




EU/2/09/104/001-002/IS


Zulvac 8 Ovis


Iceland


28.1.2010




EU/2/09/105/001/NO-002/NO


Zulvac 8 Bovis


Norway


8.2.2010




EU/2/09/105/001-002


Zulvac 8 Bovis


Liechtenstein


28.2.2010




EU/2/09/105/001-002/IS


Zulvac 8 Bovis


Iceland


27.1.2010







ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2010:








EU-Number


Product


Country


Date of authorisation




EU/1/00/129/001-003


Azopt


Liechtenstein


28.2.2010




EU/1/00/129/001-003/IS


Azopt


Iceland


16.3.2010




EU/1/00/130/001/NO-002/NO


Orgalutran


Norway


8.6.2010




EU/1/00/130/001-002


Orgalutran


Liechtenstein


30.6.2010




EU/1/00/130/001-002/IS


Orgalutran


Iceland


25.6.2010




EU/1/00/131/001/NO-005/NO


PegIntron


Norway


26.5.2010




EU/1/00/131/001-050


PegIntron


Liechtenstein


30.6.2010




EU/1/00/131/001-050/IS


PegIntron


Iceland


24.6.2010




EU/1/00/132/001/NO-050/NO


ViraferonPeg


Norway


26.5.2010




EU/1/00/132/001-050


ViraferonPeg


Liechtenstein


30.6.2010




EU/1/00/132/001-050/IS


ViraferonPeg


Iceland


25.6.2010




EU/1/00/133/001/NO-032/NO


Optisulin


Norway


25.5.2010




EU/1/00/133/001-032


Optisulin


Liechtenstein


30.6.2010




EU/1/00/133/001-032/IS


Optisulin


Iceland


25.6.2010




EU/1/00/134/001/NO-037/NO


Lantus


Norway


25.5.2010




EU/1/00/134/001-037


Lantus


Liechtenstein


30.6.2010




EU/1/00/134/001-037/IS


Lantus


Iceland


25.6.2010




EU/1/00/137/002/NO-018/NO


Avandia


Norway


7.6.2010




EU/1/00/137/002-012/IS


Avandia


Iceland


18.6.2010




EU/1/00/137/002-018


Avandia


Liechtenstein


30.6.2010




EU/1/00/140/001


Visudyne


Liechtenstein


30.6.2010




EU/1/00/140/001/IS


Visudyne


Iceland


23.6.2010




EU/1/04/272/001/NO-002/NO


PhotoBarr


Norway


17.2.2010




EU/1/04/294/001-028


Emselex


Liechtenstein


28.2.2010




EU/1/04/298/001/NO-003/NO


Kivexa


Norway


19.1.2010




EU/1/04/298/001-003


Kivexa


Liechtenstein


28.2.2010




EU/1/04/299/001/NO-003/NO


Fendrix


Norway


3.2.2010




EU/1/04/299/001-003


Fendrix


Liechtenstein


28.2.2010




EU/1/04/299/001-003/IS


Fendrix


Iceland


7.1.2010




EU/1/04/300/001/NO-002/NO


Avastin


Norway


26.1.2010




EU/1/04/300/001-002


Avastin


Liechtenstein


28.2.2010




EU/1/04/300/001-002/IS


Avastin


Iceland


11.1.2010




EU/1/04/302/001/NO-004/NO


Prialt


Norway


8.2.2010




EU/1/04/302/001-004


Prialt


Liechtenstein


28.2.2010




EU/1/04/302/001-004/IS


Prialt


Iceland


17.3.2010




EU/1/04/303/001/NO-003


Orfadin


Norway


3.2.2010




EU/1/04/303/001-003


Orfadin


Liechtenstein


28.2.2010




EU/1/04/303/001-003/IS


Orfadin


Iceland


28.1.2010




EU/1/04/304/001/NO-007/NO


Azilect


Norway


10.2.2010




EU/1/04/305/001/NO-002/NO


Truvada


Norway


3.2.2010




EU/1/04/305/001-002


Truveda


Liechtenstein


28.2.2010




EU/1/04/305/001-002/IS


Truvada


Iceland


28.1.2010




EU/1/04/306/001


Aloxi


Liechtenstein


30.4.2010




EU/1/04/306/001/IS


Aloxi


Iceland


11.5.2010




EU/1/04/306/01/NO


Aloxi


Norway


23.4.2010




EU/1/04/307/001/NO-013/NO


Zonegran


Norway


5.2.2010




EU/1/04/307/001-013


Zonegran


Liechtenstein


28.2.2010




EU/1/04/307/001-013/IS


Zonegran


Iceland


13.1.2010




EU/1/05/308/001/NO-002/NO


Aclasta


Norway


23.4.2010




EU/1/05/308/001-002


Aclasta


Liechtenstein


30.4.2010




EU/1/05/308/001-002/IS


Aclasta


Iceland


30.4.2010




EU/1/06/367/001-012


Diacomit


Liechtenstein


28.2.2010




EU/1/07/423/001-003


Vectibix


Liechtenstein


30.4.2010




EU/1/07/423/001-003/IS


Vectibix


Iceland


7.4.2010




EU/1/07/440/001-003/IS


Tyverb


Iceland


30.6.2010




EU/1/10/618/001/NO-004/NO


Prolia


Norway


14.6.2010




EU/1/99/122/001-002


Thyrogen


Liechtenstein


28.2.2010




EU/1/99/122/001-002/IS


Thyrogen


Iceland


19.2.2010




EU/1/99/123/005/NO-013/NO


Renagel


Norway


14.1.2010




EU/1/99/123/005-013


Renagel


Liechtenstein


28.2.2010




EU/1/99/123/005-013/IS


Renagel


Iceland


5.1.2010




EU/1/99/124/001/NO-002/NO


Tractocile


Norway


27.1.2010




EU/1/99/124/001-002


Tractocile


Liechtenstein


28.2.2010




EU/1/99/124/001-002/IS


Tractocile


Iceland


18.1.2010




EU/1/99/126/001/NO-021/NO


Enbrel


Norway


14.1.2010




EU/1/99/127/011/NO-044/NO


IntronA


Norway


21.4.2010




EU/1/99/127/011-039 & 041-044/IS


IntronA


Iceland


19.4.2010




EU/1/99/127/011-044


IntronA


Liechtenstein


30.4.2010




EU/2/00/018/001


Incurin


Liechtenstein


30.4.2010




EU/2/00/018/001/IS


Incurin


Iceland


21.4.2010




EU/2/00/018/001/NO


Incurin


Norway


10.5.2010




EU/2/00/019/005/NO-007/NO


Purevax FeLV


Norway


10.5.2010




EU/2/00/019/005-007


Purevax FeLV


Liechtenstein


30.4.2010




EU/2/00/019/005-007/IS


Purevax FeLV


Iceland


10.5.2010




EU/2/00/021/001-002


Rabigen SAG2


Liechtenstein


30.4.2010




EU/2/00/021/001-002/IS


Rabigen SAG2


Iceland


5.5.2010




EU/2/00/022/001a-001b,
EU/2/00/022/002a-002b,
EU/2/00/022/003a-003b,
EU/2/022/004a-004b,
EU/2/00/022/005-017


Ibaflin


Liechtenstein


30.6.2010




EU/2/00/022/003-004 a+b&007-008/IS


Ibaflin


Iceland


22.6.2010




EU/2/00/022/001-002 a+b&005-006/IS


Ibaflin


Iceland


22.6.2010




EU/2/00/22/009-017/IS


Ibaflin


Iceland


22.6.2010




EU/2/04/043/001/IS


Equilis StrepE


Iceland


14.4.2010




EU/2/04/047/001/NO-002/NO


Purevax RCPCh FeLV


Norway


24.2.2010




EU/2/04/047/001-002


Purevax RCPCh FeLV


Liechtenstein


28.2.2010




EU/2/04/047/001-002/IS


Purevax RCPCh FeLV


Iceland


15.1.2010




EU/2/04/048/001-002


Purevax RCP FeLV


Liechtenstein


28.2.2010




EU/2/04/048/001-002/IS


Purevax RCP FeLV


Iceland


9.2.2010




EU/2/04/049/001-002


Purevax RCCh


Liechtenstein


28.2.2010




EU/2/04/049/001-002/IS


Purevax RCCh


Iceland


9.2.2010




EU/2/04/051/001-002


Purevax RC


Liechtenstein


28.2.2010




EU/2/04/051/001-002/IS


Purevax RC


Iceland


9.2.2010




EU/2/04/052/001-002/IS


Purevax RCP


Iceland


9.2.2010




EU/2/04/50/001-002/IS


Purevax RCPCh


Iceland


8.2.2010




EU/2/05/053/001-003


Naxcel


Liechtenstein


30.6.2010




EU/2/99/013/001/NO-002/NO


Halocur


Norway


26.4.2010




EU/2/99/013/001-002/IS


Halocur


Iceland


15.3.2010




EU/2/99/017/001/NO-006/NO


Ibraxion


Norway


11.5.2010




EU/2/99/017/001-006/IS


Ibraxion


Iceland


25.5.2010







ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2010:








EU-Number


Product


Country


Date of authorisation




EU/1/00/152/019-020


Infanrix hexa


Liechtenstein


30.6.2010




EU/1/00/156/004


Trizivir


Liechtenstein


30.6.2010




EU/1/01/172/007


Kaletra


Liechtenstein


28.2.2010




EU/1/02/205/003/NO-004/NO


Lumigan


Norway


12.3.2010




EU/1/02/205/003-004


Lumigan


Liechtenstein


28.2.2010




EU/1/02/205/003-004/IS


Lumigan


Iceland


21.1.2010




EU/1/04/278/010-011


Levemir


Liechtenstein


30.4.2010




EU/1/04/306/002-003


Aloxi


Liechtenstein


30.6.2010




EU/1/04/306/002-003/IS


Aloxi


Iceland


11.5.2010




EU/1/05/318/002


Revatio


Liechtenstein


28.2.2010




EU/1/05/318/002/IS


Revatio


Iceland


14.1.2010




EU/1/05/318/002/NO


Revatio


Norway


18.1.2010




EU/1/05/329/006


Kiovig


Liechtenstein


30.6.2010




EU/1/06/334/005


Evoltra


Liechtenstein


28.2.2010




EU/1/06/360/013


Champix


Liechtenstein


28.2.2010




EU/1/07/384/003/NO-004/NO


Docetaxel Winthrop


Norway


1.2.2010




EU/1/07/384/003-004


Docetaxel Winthrop


Liechtenstein


28.2.2010




EU/1/07/384/005


Docetaxel Winthrop


Liechtenstein


30.6.2010




EU/1/07/386/017-018


Toviaz


Liechtenstein


28.2.2010




EU/1/07/400/022-024


Mircera


Liechtenstein


30.4.2010




EU/1/07/405/021-040


Rasilez


Liechtenstein


28.2.2010




EU/1/07/411/021-026/IS


Epoetin alfa Hexal


Iceland


3.2.2010




EU/1/07/412/021/NO-026/NO


Abseamed


Norway


13.1.2010




EU/1/07/412/021-026


Abseamed


Liechtenstein


28.2.2010




EU/1/07/440/003


Tyverb


Liechtenstein


30.6.2010




EU/1/08/444/009-012


Ratiograstim


Liechtenstein


28.2.2010




EU/1/08/445/009-014


Tevagrastim


Liechtenstein


28.2.2010




EU/1/08/450/009-010


Biograstim


Liechtenstein


28.2.2010




EU/1/08/453/002/NO


Prepandrix


Norway


9.2.2010




EU/1/08/467/002


Doribax


Liechtenstein


30.4.2010




EU/1/08/467/002/IS


Doribax


Iceland


15.6.2010




EU/1/08/494/003-004


Stelara


Liechtenstein


30.4.2010




EU/1/08/497/005/NO-008/NO


Nplate


Norway


2.2.2010




EU/1/08/497/005-008


Nplate


Liechtenstein


28.2.2010




EU/1/08/497/005-008/IS


Nplate


Iceland


22.1.2010




EU/1/09/508/010


Synflorix


Liechtenstein


28.2.2010




EU/1/09/525/047-050


Nimvastid


Liechtenstein


30.4.2010




EU/1/09/526/002


Iressa


Liechtenstein


28.2.2010




EU/1/09/528/002


Nymusa


Liechtenstein


30.6.2010




EU/1/09/538/007-008


Afinitor


Liechtenstein


30.4.2010




EU/1/09/540/010-016


Clopidogrel Teva


Liechtenstein


30.4.2010




EU/1/09/556/010-011


Clopidogrel Krka


Liechtenstein


30.4.2010




EU/1/09/557/010


Clopidogrel Qualimed


Liechtenstein


30.4.2010




EU/1/09/559/010-016


Clopidogrel Mylan


Liechtenstein


30.4.2010




EU/1/95/002/003/NO-004/NO


Taxotere


Norway


25.1.2010




EU/1/95/002/003-004


Taxotere


Liechtenstein


28.2.2010




EU/1/95/002/005


Taxotere


Liechtenstein


30.6.2010




EU/1/96/016/005/NO-006/NO


Norvir


Norway


9.2.2010




EU/1/96/016/005-006


Norvir


Liechtenstein


28.2.2010




EU/1/96/016/005-006/IS


Norvir


Iceland


12.2.2010




EU/1/97/050/028-033


Sifrol


Liechtenstein


30.6.2010




EU/1/98/069/012


Plavix


Liechtenstein


30.4.2010




EU/1/98/070/012


Iscover


Liechtenstein


30.4.2010




EU/1/98/080/002


Aldara


Liechtenstein


30.4.2010




EU/1/98/096/024-025


Temodal


Liechtenstein


28.2.2010




EU/1/97/051/028-033


Mirapexin


Liechtenstein


30.6.2010




EU/2/02/032/002


Vaxxitek HVT+IBD


Liechtenstein


30.6.2010




EU/2/04/044/011/NO-013/NO


Aivlosin


Norway


29.4.2010




EU/2/04/044/011-013


Aivlosin


Liechtenstein


28.2.2010




EU/2/04/044/011-013/IS


Aivlosin


Iceland


7.1.2010




EU/2/06/070/004/IS


Meloxidyl


Iceland


25.1.2010




EU/2/06/070/005-007


Meloxidyl


Liechtenstein


30.4.2010




EU/2/08/083/002-003


Equioxx


Liechtenstein


28.2.2010




EU/2/08/083/002-003/IS


Equioxx


Iceland


11.1.2010




EU/2/08/089/021


Onsior


Liechtenstein


28.2.2010




EU/2/08/090/009


Loxicom


Liechtenstein


30.4.2010




EU/2/97/004/035-038


Metacam


Liechtenstein


28.2.2010







ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2010:








EU-Number


Product


Country


Date of withdrawal




EU/1/00/148/001-004


Agenerase


Liechtenstein


30.6.2010




EU/1/00/148/001-004/IS


Agenerase


Iceland


29.6.2010




EU/1/06/375/001-033


Irbesartan BMS


Liechtenstein


28.2.2010




EU/1/08/471/001-012/IS


Duloxetine
Boehringer
Ingelheim


Iceland


25.6.2010




EU/1/08/471/003-005, 011-012


Duloxetine
Boehringer
Ingelheim


Liechtenstein


30.6.2010




EU/1/99/113/001-004


Paxene


Liechtenstein


28.2.2010







ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2010:








EU-Number


Product


Country


Date of suspension




EU/1/09/532/001-007


Clopidogrel Acino


Liechtenstein


30.4.2010




EU/1/09/532/001-007/IS


Clopidogrel Acino


Iceland


30.4.2010




EU/1/09/534/001-007


Clopidogrel Hexal


Liechtenstein


30.4.2010




EU/1/09/534/001-007


Clopidogrel Sandoz


Liechtenstein


30.4.2010




EU/1/09/534/001-007/IS


Clopidogrel Hexal


Iceland


30.4.2010




EU/1/09/541/001-007/IS


Clopidogrel ratiopharm GmbH


Iceland


30.4.2010




EU/1/09/541/001-008


Clopidogrel ratiopharm GmbH


Liechtenstein


30.4.2010




EU/1/09/542/001-007


Clopidogrel 1A Pharma


Liechtenstein


30.4.2010




EU/1/09/542/001-007/IS


Clopidogrel 1A Pharma


Iceland


30.4.2010




EU/1/09/547/001-007/IS


Clopidogrel Sandoz


Iceland


30.4.2010




EU/1/09/548/001-007


Clopidogrel Acino Pharma GmbH


Liechtenstein


30.4.2010




EU/1/09/548/001-007/IS


Clopidogrel Acino Pharma GmbH


Iceland


30.4.2010




EU/1/09/554/001-007/IS


Clopidogrel ratiopharm


Iceland


30.4.2010




EU/1/09/554/001-008


Clopidogrel ratiopharm


Liechtenstein


30.4.2010